December 20, 2017 05:45 AM EST

With AveXis coming up in the rear view mirror, Biogen and Ionis go back to the drawing board on SMA

John Carroll

Editor & Founder

A year after Biogen $BIIB and Ionis $IONS nailed down an approval for Spinraza to treat spinal muscular atrophy, launching one of the most expensive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With AveXis coming up in the rear view mirror, Biogen and Ionis go back to the drawing board on SMA

John Carroll

Editor & Founder

Sign up to read this article for free.

Neumora's major depression drug flunks first of three Phase 3 trials

Roche circles back to China biotech with $80M deal for lung cancer ADC

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Flagship biotech Valo Health ends 2024 with mid-stage fail

Novartis ends Phase 1 radiopharma trial; Solve Therapeutics pursues $75M round

WuXi AppTec will sell cell and gene therapy business to private equity firm

With AveX­is com­ing up in the rear view mir­ror, Bio­gen and Io­n­is go back to the draw­ing board on SMA

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Flag­ship biotech Va­lo Health ends 2024 with mid-stage fail

No­var­tis ends Phase 1 ra­dio­phar­ma tri­al; Solve Ther­a­peu­tics pur­sues $75M round

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

With AveXis coming up in the rear view mirror, Biogen and Ionis go back to the drawing board on SMA

Neumora's major depression drug flunks first of three Phase 3 trials

Roche circles back to China biotech with $80M deal for lung cancer ADC

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Flagship biotech Valo Health ends 2024 with mid-stage fail

Novartis ends Phase 1 radiopharma trial; Solve Therapeutics pursues $75M round

WuXi AppTec will sell cell and gene therapy business to private equity firm